resTORbio, which is developing a therapy to boost the immune systems of the very elderly, raised $85 million by offering 5.7 million shares at $15, within the range of $14 to $16. resTORbio plans to list on the Nasdaq under the symbol TORC. BofA Merrill Lynch, Leerink Partners and Evercore ISI acted as lead managers on the deal.
